Indeed, the Society of Surgical Oncology suggests that CPM should be considered in patients with (1) a BRCA1 or BRCA2 mutation or strongly predisposing breast cancer susceptibility genes or (2) a strong family history of at least two first-degree relatives with breast or ovarian cancer and with no demonstrable mutations [7]. This evidence concerns the gene BRCA2 and ovarian carcinoma.